Oklahoma Clinical Trials Report — May 2026

For Oklahomans considering participation in clinical research, May 2026 brings a crucial call to action, particularly for those interested in trials nearing their enrollment deadlines. Across the state, 45 clinical trials are scheduled to close within the next 90 days. This urgency is especially relevant for healthy volunteers, as 2 of these rapidly closing studies are actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, alcohol use disorder, and anxiety are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer AJCC v8
• Metastatic malignant solid neoplasm
• Primary peritoneal cancer
• Unresectable malignant solid neoplasm
• Ovarian cancer
• Alcohol use disorder
• Advanced solid tumor
• Advanced lung non-small cell carcinoma
• Anxiety
• Anatomic stage III breast cancer AJCC v8

A Singular Opportunity: New Research Focuses on Obesity and Type 2 Diabetes

This month, Oklahoma saw the launch of just 1 new clinical trial, a significant decrease compared to the 6 trials that opened in April 2026 and a stark contrast to the 20 new trials in December 2025. This makes the new opportunity particularly noteworthy for those who qualify.

The single new trial is a significant Phase 3 drug study sponsored by Novo Nordisk A/S, a major pharmaceutical company known for its work in diabetes and obesity. This trial offers a chance to participate in cutting-edge research for a widespread health challenge.

• Novo Nordisk A/S is sponsoring NCT07564414, titled "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This substantial trial aims to enroll 2,500 participants globally, evaluating the safety and effectiveness of the study medicine CagriSema for body weight loss in individuals living with obesity, with or without type 2 diabetes (T2D).

This new study is specifically targeting conditions of obesity and type 2 diabetes, offering a new avenue for individuals managing these health concerns to explore potential new treatments. It is the only new drug trial to open in Oklahoma this month.

Geographic Accessibility and Participation Pathways

While the new trial this month is located in Norman, Oklahoma offers a broad landscape for clinical research overall. Currently, there are 792 clinical trials actively recruiting across 23 cities and 406 research sites statewide. This wide distribution ensures that many Oklahomans have access to research opportunities close to home, even if new trial openings are concentrated in specific areas.

For individuals without a specific medical condition, there are consistent opportunities to contribute. Although the single new trial this month does not accept healthy volunteers, a total of 57 clinical trials are currently recruiting healthy participants statewide. These studies play a vital role in understanding normal bodily functions and testing new interventions, providing numerous avenues for those interested in supporting medical research.

Eligibility for the new trial includes older adults, ensuring that senior populations have an opportunity to contribute to medical science. No new trials this month are exclusively for females or males, nor do they include children.

The research landscape in Oklahoma is dynamic, with industry sponsors like Novo Nordisk A/S driving significant efforts in areas like metabolic health. As we move through May, the focus will likely remain on the ongoing enrollment in these important Phase 3 trials, while researchers prepare for future studies to address a broad spectrum of health challenges across Oklahoma.